Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database

Background Four CGRP Monoclonal Antibodies (mAbs) have been approved for migraine prophylaxis by the Food and Drug Administration (FDA) since 2018. However, there are concerns about the safety of these four drugs for real-world use.